Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But if ...

Pfizer Inc. (NYSE:PFE – Get Free Report) saw unusually large options trading activity on Thursday. Traders acquired 251,131 ...

Pfizer's stock experienced a notable decline on Friday at the New York Stock Exchange, falling 1.6% to $26.03 per share following news of a $59.7 million settlement payment. The settlement stems from ...

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at ...

Equities research analysts at Zacks Research upped their Q1 2026 earnings per share estimates for Pfizer in a report released ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The ...

That's especially the case when you invest in stocks that pay you to own them. I'm referring to dividend stocks, of course.